Alnylam Pharmaceuticals, 675 West Kendall, Cambridge, Massachusetts 02142, United States.
Department of Biochemistry, School of Medicine, Vanderbilt University, Nashville, Tennessee 37232, United States.
J Am Chem Soc. 2022 Aug 17;144(32):14517-14534. doi: 10.1021/jacs.2c01679. Epub 2022 Aug 3.
Although 2'-deoxy-2'-α-F-2'-β--methyl (2'-F/Me) uridine nucleoside derivatives are a successful class of antiviral drugs, this modification had not been studied in oligonucleotides. Herein, we demonstrate the facile synthesis of 2'-F/Me-modified pyrimidine phosphoramidites and their subsequent incorporation into oligonucleotides. Despite the C3'- preorganization of the parent nucleoside, a single incorporation into RNA or DNA resulted in significant thermal destabilization of a duplex due to unfavorable enthalpy, likely resulting from steric effects. When located at the terminus of an oligonucleotide, the 2'-F/Me modification imparted more resistance to degradation than the corresponding 2'-fluoro nucleotides. Small interfering RNAs (siRNAs) modified at certain positions with 2'-F/Me had similar or better silencing activity than the parent siRNAs when delivered via a lipid nanoparticle formulation or as a triantennary -acetylgalactosamine conjugate in cells and in mice. Modification in the seed region of the antisense strand at position 6 or 7 resulted in an activity equivalent to the parent in mice. Additionally, placement of the antisense strand at position 7 mitigated seed-based off-target effects in cell-based assays. When the 2'-F/Me modification was combined with 5'-vinyl phosphonate, both and isomers had silencing activity comparable to the parent. In combination with other 2'-modifications such as 2'--methyl, the isomer is detrimental to silencing activity. Presumably, the equivalence of 5'-vinyl phosphonate isomers in the context of 2'-F/Me is driven by the steric and conformational features of the -methyl-containing sugar ring. These data indicate that 2'-F/Me nucleotides are promising tools for nucleic acid-based therapeutic applications to increase potency, duration, and safety.
尽管 2'-脱氧-2'-α-F-2'-β--甲基(2'-F/Me)尿嘧啶核苷衍生物是一类成功的抗病毒药物,但这种修饰在寡核苷酸中尚未得到研究。在此,我们展示了嘧啶磷酰胺类似物的简便合成及其随后在寡核苷酸中的掺入。尽管母体核苷的 C3'-预组织,但由于不利的焓,单个掺入 RNA 或 DNA 会导致双链体显著热不稳定性,可能是由于空间位阻效应所致。当位于寡核苷酸的末端时,2'-F/Me 修饰赋予比相应的 2'-氟核苷酸更高的抗降解能力。在某些位置用 2'-F/Me 修饰的小干扰 RNA (siRNA) 经脂质纳米颗粒制剂或三触角乙酰半乳糖胺缀合物递送至细胞和小鼠中时,其沉默活性与母体 siRNA 相似或更好。反义链在位置 6 或 7 的种子区域进行修饰会导致在小鼠中的活性与母体相当。此外,反义链在位置 7 的放置减轻了基于种子的脱靶效应在细胞测定中。当 2'-F/Me 修饰与 5'-乙烯基膦酸酯结合时,和 异构体都具有与母体相当的沉默活性。与其他 2'-修饰(如 2'---甲基)结合时,异构体对沉默活性有害。据推测,在 2'-F/Me 背景下 5'-乙烯基膦酸酯异构体的等效性是由含--甲基的糖环的空间和构象特征驱动的。这些数据表明,2'-F/Me 核苷酸是用于基于核酸的治疗应用的有前途的工具,可以提高效力、持续时间和安全性。